RxDoctor Payments Data

Debra Schexnayder, NP

Nurse Practitioner · Harvey, LANPI 1073557872

Payments from drug & device makers

$3,819in general payments, 2019–2025

Across 181 payments — averaging $21.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$886
  • AstraZeneca$761
  • AbbVie$541
  • Boehringer Ingelheim$249
  • GSK$247
  • Dexcom, Inc.$193
  • plus $942 from 15 others

What the payments were for

  • Food & beverage$3,819100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,819 in reported general payments places this provider in the 85th percentile of 969 nurse practitioner providers in Louisiana.

See all nurse practitioner providers in Louisiana

Medicare billing

Part B allowed, 2024
$23,105
Medicare patients
196
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$21,393
Spiriva HandihalerTiotropium Bromide11$10,074
JanuviaSitagliptin Phosphate11$9,968
Albuterol Sulfate HfaAlbuterol Sulfate43$1,188
Pantoprazole Sodium84$731
Rosuvastatin Calcium57$723
Levothyroxine Sodium55$695
Fluticasone Propionate38$685
Gabapentin51$601
Atorvastatin Calcium101$597
Tizanidine Hcl45$557
Amlodipine Besylate94$491
ValacyclovirValacyclovir Hcl17$476
Omeprazole36$385
Metoprolol Succinate34$366

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$179$21,39328 claims
MerckJanuvia$27$9,96811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 969 nurse practitioner providers in Louisiana.

Other nurse practitioner in Harvey

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →